EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A safety study of ultra‐high dose rate FLASH radiotherapy in the treatment of superficial skin tumors: study protocol of a phase I trial (ChiCTR2400080935)

Chengliang Yang, Hui Luo, Ma Leijie, Ronghu Mao, Hongchang Lei, Yanping Zhang, Meng Xu, Yiwu Wang, Mingxia Wu, Han Liu, Peng Chen, Hong Ge

Precision Radiation Oncology · 2025-06 · 9 (2) · 72-76

DOI: 10.1002/pro6.70010 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objective Ultra‐high dose rate FLASH radiotherapy (FLASH‐RT) is emerging as a novel technique to improve the normal tissue tolerance by delivering ultra‐high dose rate radiation several orders of magnitude higher than convention radiotherapy. It has been shown in preclinical studies to cause less injury to surrounding normal tissues during radiation treatment, while still maintaining local tumor control. The purpose of this protocol is to evaluate the safety of fractionated FLASH‐RT in skin cancer. Method Patients with superficial skin tumors will be enrolled. The eligible patients will undergo electron FLASH‐RT (24‐40 Gy/3‐5 fractions) to the tumor volume. The primary outcome is to evaluate the safety of FLASH‐RT by collecting the acute (< 90 days) skin toxicity adverse events of radiation according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Secondary objectives include late (> 90 days) skin toxicity after FLASH‐RT according to CTCAE version 5.0 and treatment response. Discussion If the results show that delivering FLASH‐RT is safe and feasible for skin tumors, further investigation will be conduct to evaluate efficacy of FLASH‐RT in a phase II trial. Trial Registration number ChiCTR2400080935. https://www.chictr.org.cn/showproj.html?proj=220336

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →